Follow the Money: The Smart Capital Already Voted on What 2030 Looks Like
Key takeaways:
Private equity firm Thoreau Group signed a $12 billion agreement to acquire RCM company Ensemble Health Partners in 2026, one of the largest revenue cycle transactions on record.
Revenue cycle management is consolidating fast: IKS Health acquired TruBridge, Med-Metrix completed back-to-back acquisitions, and Innovaccer folded CaduceusHealth into its platform, all in the first half of 2026.
Ascension completed its $3.9 billion acquisition of Amsurg, growing its ambulatory surgery center network to roughly 300 facilities, while physician groups hit a record 46% of all healthcare transactions in Q1 2026.
U.S. digital health companies raised $7.4 billion in the first half of 2026, with 45% of that capital concentrated in megadeals of $100 million or more.
Rock Health stopped counting AI as a differentiator in its market analysis because every company claims it. The new question investors ask: who has something AI alone can't provide?
Somewhere in the middle of a venture funding roundup this month, wedged between a wearables IPO rumor and a peptide startup raising three million dollars, sat a number that should have stopped every hospital CFO in America: $12 billion.
That's the agreement Matt Holt's Thoreau Group signed to acquire Ensemble Health Partners, a revenue cycle management company. Not a health system. Not a payer. Not a shiny AI startup. A company whose entire business is the unglamorous work of getting hospitals paid.
Private equity does not write twelve-billion-dollar checks on a hunch. When capital moves at that scale, it means the due diligence is done, the model is built, and somebody with very expensive analysts has already decided what the next five years look like. They read the map. Most hospital strategic plans are still arguing about the legend.
I wrote in RCM 2030 that the cost and complexity of modernizing revenue cycle technology would strain budgets and drive consolidation, and that payer-owned platforms would blur the line between partnership and dependency. This summer, three threads of evidence converged that say the timeline is not 2030. The timeline is now.
Why is revenue cycle management consolidating so fast?
The Ensemble deal is the headline, but it is not alone. In the first half of 2026, IKS Health acquired TruBridge in a $557 million deal to extend its RCM platform into rural communities. Med-Metrix completed back-to-back acquisitions of Vitalware and CanAide. Innovaccer folded CaduceusHealth into its platform to offer end-to-end revenue cycle management. Rock Health counted 115 digital health acquisitions in the first six months of the year, pacing well ahead of both 2025 and 2024, and named revenue cycle management as one of the most active sectors for consolidation.
The logic is simple, and it's the same logic I laid out in the book: hospitals cannot afford a dozen bolt-on vendors anymore. Vendor sprawl was survivable when margins were fatter and AI licensing hadn't repriced every contract. It isn't survivable now. The market is converging on revenue intelligence platforms, one environment where EHR, billing, and payer data actually talk to each other. In a margin-thin decade, redundancy dies first.
The buyers know this. That's why they're paying premium prices to assemble platforms while hospitals are still running RFPs for point solutions. Every acquisition on that list is a bet that health systems will consolidate their vendor stacks onto fewer, bigger partners, and that the partners left standing will have pricing power their customers can only dream about.
Ask yourself who has more leverage in a 2028 contract negotiation: a hospital with a rationalized vendor stack and outcome-based contract terms, or a hospital that waited until its four RCM vendors became one RCM vendor with a private equity board and a growth target?
What does the ASC land grab mean for hospitals?
Thread two is happening in plain sight. Ascension completed its $3.9 billion acquisition of Amsurg this summer, expanding its ambulatory surgery center network to roughly 300 facilities. One month later, Amsurg bought five more endoscopy centers in North Carolina. Cleveland Clinic partnered with Regent Surgical to develop ASCs across several markets. Bon Secours Mercy Health struck a deal to develop more than 30 ASCs. ChristianaCare and Parkview Health formed their own surgery center joint ventures.
The underlying math explains the urgency. Kaufman Hall's National Hospital Flash Report found outpatient revenue per calendar day grew 8% year over year through May 2026, compared to 5% for inpatient revenue, while total expenses grew faster than total revenue. And per PwC's midyear deals outlook, physician medical groups accounted for a record 46% of all healthcare transactions in the first quarter of 2026, generating nearly three times as many deals as any other subsector.
Kaufman Hall's Erik Swanson put the stakes in one sentence: hospitals without an outpatient footprint will struggle.
In RCM 2030, I warned CFOs to model the hit from expanding site-neutral payment policies, because the hospital outpatient premium you're counting on is exactly the margin regulators want to compress. The systems buying ASC networks right now aren't just following patients out of the building. They're repositioning before the payment rules finish changing. When the same procedure pays the same rate regardless of setting, you want to own the low-cost setting. The buyers already do the math that way. The question is whether your strategic plan does.
Where is digital health investment actually going in 2026?
Thread three is the quietest and the most telling. U.S. digital health companies raised $7.4 billion across 244 deals in the first half of 2026, beating last year's pace. But look at the shape of the money: 45% of all capital went into just 20 megadeals. The capital is not spreading its bets. It's concentrating them.
Concentrating on what? Infrastructure. Pearl Health raised $110 million led by Andreessen Horowitz to build AI-powered infrastructure for Medicare providers; the company reached profitability in 2025 and now manages $3.6 billion in annualized medical spend. Aledade secured a $500 million credit facility. Strive Health pulled in $550 million between equity and debt. These are not app bets. These are bets on owning the operational layer that value-based care runs on.
And then there's the finding from Rock Health that deserves its own paragraph: the firm stopped labeling AI as a distinguishing product or strategy, because every company claims it now. Investors have moved on to a sharper question, and it's the one I'd frame this whole year around: who has something AI alone can't provide?
Read those three threads together and the picture resolves. The smart money is not betting on hospitals adopting AI. The smart money is betting on owning the layer hospitals will have to rent: the consolidated RCM platforms, the outpatient settings, the value-based care infrastructure. Rent is a fine business model. For the landlord.
What should health system leaders do about it?
Three moves before your next board meeting.
First, rationalize your vendor stack before the market does it for you. Every RCM acquisition this year shrinks your future negotiating table. Run a real audit of which tools solve root causes and which ones mop up after broken processes, and take the wind-down list into renewal season with you. I built a free field guide for exactly this exercise; you can download the AI Value Audit here. It takes 30 days and costs you nothing but honesty.
Second, model your site-neutral exposure now, not in 2029. Take your top 20 hospital outpatient service lines and calculate what happens to margin if they reimburse at ASC or physician office rates. That number is your urgency metric for outpatient strategy, and it's the number the acquirers ran before they wrote their checks.
Third, renegotiate toward outcomes while you still have leverage. As RCM vendors consolidate, contingency-fee and activity-based contracts will age badly. Push for outcome terms now: net collections, first-pass yield, denial prevention, estimate accuracy. The vendors who won't sign outcome-based terms in 2026 are telling you something about their 2028 roadmap.
None of this requires you to predict the future. The future already filed its paperwork with the SEC. All you have to do is read what the money already read.
I wrote RCM 2030: Strategy and Survival for Revenue Cycle Leaders because the changes coming to healthcare under this administration's mandates and priorities are moving faster than most strategic plans, and leaders need to start preparing now for what 2030 will look like. The book covers the full map: AI-driven adjudication, payer strategy, policy shocks, cybersecurity, workforce modernization, and the checklists to get ahead of all of it. Grab it on Amazon and gird your loins today.
And if you want this analysis every week, RCM 2030 Weekly publishes every Sunday on LinkedIn. Search for RCM 2030 Weekly and hit subscribe.
Frequently Asked Questions
What was the biggest RCM deal of 2026? The largest revenue cycle management transaction announced in 2026 is Thoreau Group's $12 billion agreement to acquire Ensemble Health Partners, a healthcare revenue cycle management company serving hospitals and health systems.
Why are health systems buying ambulatory surgery centers? Outpatient revenue is growing faster than inpatient revenue (8% vs. 5% year over year through May 2026, per Kaufman Hall), payers and patients both prefer lower-cost settings, and anticipated expansion of site-neutral payment policies threatens the traditional hospital outpatient payment premium. Owning ASCs lets health systems capture procedures in the setting where the economics are heading.
Is AI still a competitive advantage for healthcare companies? Not by itself. Rock Health stopped counting AI as a differentiator in its 2026 market analysis because nearly every digital health company now claims AI capabilities. Investors instead evaluate what a company has that AI alone can't provide: domain expertise, workflow ownership, delivery infrastructure, and trusted partnerships.
What is site-neutral payment and why does it matter for hospitals? Site-neutral payment means Medicare reimburses the same service at the same rate regardless of whether it's performed in a hospital outpatient department, an ambulatory surgery center, or a physician office. Expansion of these policies would compress the payment premium hospitals currently receive for outpatient services, which is why modeling that exposure now is a core recommendation in RCM 2030.
How should hospitals prepare for RCM vendor consolidation? Audit the vendor stack before renewal season: identify which tools solve root causes versus patching broken processes, consolidate onto platforms where possible, and shift contracts toward outcome-based terms like net collections and first-pass yield while multiple vendors are still competing for the business.
